Neuropathic pain is a well-known type of
chronic pain caused by damage to the nervous system. Autophagy is involved in the development and/or progression of many diseases, including
neuropathic pain. Emerging evidence suggests that
metformin relieves
neuropathic pain in several
neuropathic pain models; however,
metformin's cellular and molecular mechanism for
pain relief remains unknown. In this study, we investigated the
therapeutic effects of
metformin on
pain relief after spinal nerve
ligation (SNL) and its underlying mechanism of autophagy regulation. Behavioural analysis, histological assessment, expression of c-Fos and molecular biological changes, as well as ultrastructural features, were investigated. Our findings showed that the number of autophagosomes and expression of autophagy markers, such as LC3 and
beclin1, were increased, while the autophagy substrate
protein p62, as well as the
ubiquitinated proteins, were accumulated in the ipsilateral spinal cord. However,
metformin enhanced the expression of autophagy markers, while it abrogated the abundance of p62 and
ubiquitinated proteins. Blockage of autophagy flux by
chloroquine partially abolished the apoptosis inhibition and
analgesic effects of
metformin on SNL. Taken together, these results illustrated that
metformin relieved
neuropathic pain through autophagy flux stimulation and provided a new direction for
metformin drug development to treat
neuropathic pain.